Arrhythmia Alliance SVT Healthcare Pioneers
Showcasing Best Practice in SVT
Apply to be a Healthcare Pioneer
Centres of Excellence
Apply to be a Centre of Excellence
Supraventricular tachycardia (SVT) is a rapid increase in resting heart rate (above 100 beats per minute) that, as the name suggests, originates in the atria. In the USA, it has an approximate prevalence of 140 per 100,000 and an incidence of 73 per 100,000.1 Furthermore, Go et al estimate “that at least 393,810 Americans experience symptomatic, sustained SVT”. They add that the burden of SVT is “notably higher” in “older people, women, those of white or black race, and those with cardiovascular disease (coronary disease or heart failure) or major cardiovascular risk factors (chronic kidney disease, diabetes mellitus, or hypertension)”.
The diagnosis of SVT can be difficult given the episodic nature of the condition — i.e., the need to record an EKG when an event occurs. Another challenge is that while medications (such as beta-blockers) and interventions (such as ablation) are available to reduce the frequency and duration of symptoms, people with SVT may continue to have episodes. Additionally, because of finding the side-effects intolerable, some patients discontinue taking medication.2
To help address these challenges, Arrhythmia Alliance has launched its Healthcare Pioneers Report — Showcasing Best Practice in SVT. The aim of the report is to provide examples of good care to inspire centers around the world to improve care and quality of life for people with SVT. This is in keeping with the established AF Association Healthcare Pioneers Report — Showcasing Best Practice in AF (distributed during Global AF Aware Week) and the STARS Healthcare Pioneers Report — Showcasing Best Practice in Syncope (distributed during World Heart Rhythm Week).
For its inaugural report, Arrhythmia Alliance invited centers of excellence in North America and Europe to submit case studies outlining innovative approaches to managing SVT. The submitted case studies, published in this report, include reviewing the value of using a 12-lead EKG to diagnose SVT, the role of personal EKGs to aid diagnosis during the COVID-19 pandemic, and home management of SVT.
For its next report, Arrhythmia Alliance wants all centers of excellence to showcase their innovative work in managing SVT. Therefore, submissions for the Arrhythmia Alliance Healthcare Pioneers Report — Showcasing Best Practice in SVT 2022 will open on 7th June, marking the start of World Heart Rhythm Week (7–13 June 2021), on the dedicated SVT Pioneers website. The winning case studies, submitted via the site, will be published in the report, which will be promoted and distributed during National Heart Month 2022. The winning teams will also receive a certificate that acknowledges them as an SVT Pioneer and their center will be listed as a “Center of Excellence” on the dedicated SVT Pioneers website. However, you can apply to be a Center of Excellence now — CLICK HERE.
- Go AS, Hlatky MA, Liu TI, et al. Contemporary burden and correlates of symptomatic paroxysmal supraventricular tachycardia. J Am Heart Assoc 2018; 7: e008759
- Milestone Pharmaceuticals. Paroxysmal supraventricular tachycardia (PSVT). http://bit.ly/2ZTDezg (Date accessed: 26/02/21)